• 论坛首页
  • 我的丁香客
  • 找人
    查找好友
  • 更多
    丁香园
    丁香通
    丁香人才
    丁香会议
    丁香搜索
    丁香医生
    丁香无线
    丁香导航
    丁当铺
    文献求助
    医药数据库
    丁香诊所
    来问医生
登录 注册

科技动态

关注今日:2 | 主题:423237
论坛首页  >  医药生命科学动态跟踪   >  感染
  • 发帖
    每发1个新帖
    可以获得0.5个丁当奖励
  • 回帖

分享到:

  • 微信

    微信扫一扫

  • 微博
  • 丁香客
  • 复制网址

【medical-news】新英格兰医学杂志发表泰国艾滋疫苗临床试验结果

  • 查看全部
  • 页码直达:
  • 直达末页
楼主 freelane
freelane
铁杆站友

  • 515
    积分
  • 3846
    得票
  • 1.2万
    丁当
  • 1楼
这个帖子发布于11年零97天前,其中的信息可能已发生改变或有所发展。
新英格兰医学杂志发表泰国艾滋疫苗临床试验结果

Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand

ABSTRACT

Background The development of a safe and effective vaccine against the human immunodeficiency virus type 1 (HIV-1) is critical to pandemic control.

Methods In a community-based, randomized, multicenter, double-blind, placebo-controlled efficacy trial, we evaluated four priming injections of a recombinant canarypox vector vaccine (ALVAC-HIV [vCP1521]) plus two booster injections of a recombinant glycoprotein 120 subunit vaccine (AIDSVAX B/E). The vaccine and placebo injections were administered to 16,402 healthy men and women between the ages of 18 and 30 years in Rayong and Chon Buri provinces in Thailand. The volunteers, primarily at heterosexual risk for HIV infection, were monitored for the coprimary end points: HIV-1 infection and early HIV-1 viremia, at the end of the 6-month vaccination series and every 6 months thereafter for 3 years.

Results In the intention-to-treat analysis involving 16,402 subjects, there was a trend toward the prevention of HIV-1 infection among the vaccine recipients, with a vaccine efficacy of 26.4% (95% confidence interval [CI], –4.0 to 47.9; P=0.08). In the per-protocol analysis involving 12,452 subjects, the vaccine efficacy was 26.2% (95% CI, –13.3 to 51.9; P=0.16). In the modified intention-to-treat analysis involving 16,395 subjects (with the exclusion of 7 subjects who were found to have had HIV-1 infection at baseline), the vaccine efficacy was 31.2% (95% CI, 1.1 to 51.2; P=0.04). Vaccination did not affect the degree of viremia or the CD4+ T-cell count in subjects in whom HIV-1 infection was subsequently diagnosed.

Conclusions This ALVAC-HIV and AIDSVAX B/E vaccine regimen may reduce the risk of HIV infection in a community-based population with largely heterosexual risk. Vaccination did not affect the viral load or CD4+ count in subjects with HIV infection. Although the results show only a modest benefit, they offer insight for future research. (ClinicalTrials.gov number, NCT00223080 [ClinicalTrials.gov] .)

临床论文全文下载
http://content.nejm.org/cgi/content/full/NEJMoa0908492
  • 邀请讨论
  • 不知道邀请谁?试试他们

    换一换
2009-10-25 14:14 浏览 : 2126 回复 : 8
  • 投票
  • 收藏 2
  • 打赏
  • 引用
  • 分享
    • 微信扫一扫

    • 新浪微博
    • 丁香客
    • 复制网址
  • 举报
    • 广告宣传推广
    • 政治敏感、违法虚假信息
    • 恶意灌水、重复发帖
    • 违规侵权、站友争执
    • 附件异常、链接失效
    • 其他
  • • 首张“新冠患者分子全景图”

关闭提示

需要2个丁当

丁香园旗下网站

  • 丁香园
  • 用药助手
  • 丁香通
  • 文献求助
  • 丁香人才
  • 丁香医生
  • 丁香导航
  • 丁香会议
  • 手机丁香园
  • 医药数据库

关于丁香园

  • 关于我们
  • 丁香园标志
  • 友情链接
  • 联系我们
  • 加盟丁香园
  • 版权声明
  • 资格证书

官方链接

  • 丁香志
  • 丁香园新浪微博
引用回复